ConferencePoster
 (2024)

Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer